We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Ocular Therapeutix Inc (OCUL) USD0.0001

Sell:$4.84 Buy:$5.68 Change: $0.62 (10.49%)
NASDAQ:2.05%
Market closed |  Prices as at close on 19 April 2024 | Switch to live prices |
Sell:$4.84
Buy:$5.68
Change: $0.62 (10.49%)
Market closed |  Prices as at close on 19 April 2024 | Switch to live prices |
Sell:$4.84
Buy:$5.68
Change: $0.62 (10.49%)
Market closed |  Prices as at close on 19 April 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. It is also developing two other clinical-stage assets, OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease, and OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease. It is conducting a pivotal Phase III clinical trial to evaluate AXPAXLI for the treatment of wet AMD. Its clinical portfolio also includes PAXTRAVA, which is in Phase III clinical development for the treatment of primary open-angle glaucoma (OAG) or ocular hypertension (OHT).

Contact details

Address:
15 Crosby Drive
BEDFORD
01730
United States
Telephone:
+1 (781) 3574000
Website:
https://www.ocutx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
OCUL
ISIN:
US67576A1007
Market cap:
$1.13 billion
Shares in issue:
148.63 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Pravin Dugel
    Executive Chairman of the Board, President, Chief Executive Officer
  • Donald Notman
    Chief Financial Officer
  • Peter Jarrett
    Chief Technical Officer
  • Jeffrey Heier
    Chief Scientific Officer
  • Philip Strassburger
    General Counsel
  • Peter Kaiser
    Chief Development Officer
  • Steve Meyers
    Chief Commercial Officer
  • Sanjay Nayak
    Chief Strategy Officer
  • Rabia Ozden
    Chief Medical Officer
  • Nadia Waheed
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.